| Date | Title | Description | |
|---|---|---|---|
| 08 May 2025 | On business and financial situation | The Company releases the first three months 2025 financial results presentation | Download |
| 08 May 2025 | Announcement of General Shareholders’ Meeting | The Company announces the call of its 2025 Ordinary General Shareholders' Meeting | Download |
| 08 May 2025 | On business and financial situation | ROVI informs on the award of a grant in its favor to develop the R&D Project IPCEI - ROVI (LAISOLID) | Download |
| 08 May 2025 | On business and financial situation | The Company releases the press release related to the first three months of 2025 financial results | Download |
| 04 Apr 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the first quarter of 2025 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 10 May 2018 | Otros sobre negocio y situación financiera | Update pivotal PRISMA-3 study of DORIA® (Risperidone ISM®) | Download |
| 25 Apr 2018 | Información sobre resultados | ROVI releases the press release related to the 2018 first quarter financial results | Download |
| 25 Apr 2018 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI informs about the call for the 2018 Ordinary General Shareholders Meeting | Download |
| 25 Apr 2018 | Información sobre resultados | ROVI releases the 2018 first quarter results presentation | Download |
| 04 Apr 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2018 | Download |